



Occupational exposures and small airway obstruction in the UK Biobank Cohort

Johanna Feary¹, Valentina Quintero-Santofimio¹, James Potts¹, Roel Vermeulen², Hans Kromhout², Ben Knox-Brown¹ and Andre F.S. Amaral¹

¹National Heart and Lung Institute, Imperial College London, London, UK. ²Institute for Risk Assessment Sciences, University of Utrecht, Utrecht, The Netherlands.

Corresponding author: Johanna Feary (j.feary@imperial.ac.uk)



Shareable abstract (@ERSpublications)

A history of occupational exposure to pesticides, particularly at high levels, may contribute to the development of small airway obstruction. This relationship is independent of age, sex, cigarette smoking and socioeconomic status. <https://bit.ly/3TkmsKQ>

Cite this article as: Feary J, Quintero-Santofimio V, Potts J, *et al.* Occupational exposures and small airway obstruction in the UK Biobank Cohort. *ERJ Open Res* 2023; 9: 00650-2022 [DOI: 10.1183/23120541.00650-2022].

Copyright ©The authors 2023

This version is distributed under the terms of the Creative Commons Attribution Licence 4.0.

Received: 27 Nov 2022
Accepted: 8 March 2023

Abstract

Background Small airways obstruction (SAO) is a key feature of both COPD and asthma, which have been associated with workplace exposures. Whether SAO, which may occur early in the development of obstructive lung disease and without symptoms, also associates with occupational exposures is unknown.

Methods Using UK Biobank data, we derived measurements of SAO from the 65 145 participants with high-quality spirometry and lifetime occupational histories. The ALOHA+ Job Exposure Matrix was used to assign lifetime occupational exposures to each participant. The association between SAO and lifetime occupational exposures was evaluated using a logistic regression model adjusted for potential confounders. A second logistic regression model was also run to account for potential co-exposures.

Results SAO was present in varying proportions of the population depending on definition used: 5.6% (forced expiratory flow between 25 and 75% of the forced vital capacity (FEF_{25–75}) < lower limit of normal (LLN)) and 21.4% (forced expiratory volume in 3 s (FEV₃)/forced expiratory volume in 6 s (FEV₆) <LLN). After adjustment for confounders and co-exposures, people in the highest category of exposure to pesticides were significantly more likely to have SAO (FEV₃/FEV₆ <LLN: OR 1.24, 95% CI 1.06–1.44). The association between pesticides and SAO showed an exposure-response pattern. SAO was also less likely among people in the highest exposure categories of aromatic solvents (FEV₃/FEV₆ <LLN: OR 0.85, 95% CI 0.73–0.99) and metals (FEV₃/FEV₆ <LLN: OR 0.77, 95% CI 0.62–0.94).

Conclusion Our findings suggest that occupational exposure to pesticides play a role in the SAO. However, further work is needed to determine causality, and identify the specific component(s) responsible and the underlying mechanisms involved.

Introduction

An estimated 15% of COPD and of adult-onset asthma may be caused by workplace respiratory exposures [1]. A key feature of COPD and some asthma is damage to the small airways (<2 mm diameter), which show a dramatic increase in resistance [2]. Studies in ever-smokers and hospital-based populations suggest that small airways obstruction (SAO) precedes spirometric evidence of COPD, radiological detection of emphysema and asthma diagnosis [3–6]. Identification of early subclinical SAO provides an opportunity to intervene with assessment of and, if appropriate, interventions to reduce harmful workplace exposures that may be contributing to the development of respiratory diseases.

Small airways function can be assessed using different methods, including body plethysmography, impulse oscillometry or forced oscillation technique, nitrogen wash out, high-resolution computed tomography, hyperpolarised magnetic resonance imaging and spirometry.



Evaluation of lung health through spirometry is a cornerstone of occupational health surveillance and of clinical evaluation in the healthcare setting. With the growing interest in the life course evolution of lung function, there has been a resurgence of interest in the potential of mid-expiratory flow (MEF) rates, measured by spirometry, to identify early subclinical SAO amongst those who would otherwise be considered to be healthy on the basis of having a ratio of forced expiratory volume in 1 s (FEV₁) and forced vital capacity (FVC) (FEV₁/FVC) comparable to population reference equations [7–10]. Conversely, QUANJER *et al.* [11] showed that there was little discordance between airway obstruction diagnosed by the use of FEV₁/FVC compared to the use of MEF rates, with the greatest difference between the two measures observed in younger age groups. Because of the scarce and limited research conducted on this topic, clinicians rarely consider low MEFs in isolation as relevant in the diagnostic process. As a result, recent research has focused on the use of the FEV in 3 s as a ratio of the FVC (FEV₃/FVC) or of the FEV in 6 s (FEV₃/FEV₆) to detect SAO [6, 12]. Both of these ratios account for variation in the FVC and are therefore subject to less measurement error than the MEF.

There is limited evidence on the association between occupational exposures and SAO. Small occupational studies have reported associations of SAO with particular exposures such as, for example, fungi and mineral dust [13]. However, to date, these studies have been restricted to working populations, which can introduce bias from healthy worker effect. Two European population-based studies, one in the Netherlands and one in Spain, have reported associations of SAO with workplace exposures to vapours, gases, dusts and fumes [14, 15]. However, neither investigated which specific occupational exposures put workers at increased risk of SAO.

Here, we use the UK Biobank population cohort, which comprises the largest dataset of lung function measurements collected in the world, to identify occupational risk factors for SAO using a job exposure matrix to assign occupational exposures and to assess longitudinal changes in SAO.

Methods

The UK Biobank population cohort

UK Biobank recruited over 500 000 participants aged 40–69 years from 22 different centres across England, Wales and Scotland, between 2006 and 2010 [16]. Following written informed consent, participants completed a baseline assessment consisting of a detailed questionnaire, recording of self-reported medical history, and clinical assessment which included spirometry measurement. Records were obtained for 502 414 individuals. The study was approved by the UK National Research Ethics Service Committee North West – Haydock.

Definition of SAO

Spirometry was performed using a calibrated Vitalograph Pneumotrac 6800. Quality control was conducted on the spirometry data following previously described criteria [17]. In brief, to have the highest quality spirometry, participants had to have a minimum of two spirograms fulfilling all the following criteria: no cough, back-extrapolated volume <5% FVC (or >5% but <150 mL), reproducible FEV₁ and FVC, and a forced expiratory time of ≥6 s on the best curve (curve with highest FEV₁ and FVC).

Spirometry-derived data were readily available for FEV₁ and FVC in the UK Biobank. We also extracted from the raw data the values for FEV₃ and FEV₆ and mean forced expiratory flow between the 25% and 75% of the FVC (FEF_{25–75}) which were required to define SAO. Owing to lack of literature agreement on which spirometry parameter is best to define SAO [18], three different spirometry parameters (FEF_{25–75}, FEV₃/FVC and FEV₃/FEV₆) were considered, *a priori*, in the analysis. When we explored the data further, we found that the mean FEV₆ and FVC values were very similar (3.74 L and 3.77 L respectively) suggesting that the FVC is likely to be underestimated (as a result of the spirometry protocol used in UK Biobank). This leads to a falsely elevated FEV₃/FVC ratio and an apparent underestimation of the prevalence of SAO. We therefore chose to define SAO as FEF_{25–75} or FEV₃/FEV₆ below the lower limit of normal (LLN), based on HANKINSON *et al.* 1999 [19] and HANSEN 2014 *et al.* [20] reference equations.

Lifetime occupational exposures

Participants in the UK Biobank self-coded their job using a three-level tree categorisation system, OSCAR (Occupations Self-Coding Automatic Recording), based on the Standard Occupational Classification 2000 (SOC2000) [21] to identify each paid job held for >6 months [22]. In the UK Biobank, the job code is reported as a six-digit number, where the first four digits correspond to the SOC2000. To assign lifetime occupational respiratory exposures to each UK Biobank participant, the ALOHA+ Job Exposure Matrix (JEM) was used. The ALOHA+ JEM is based on expert assessment by industrial hygienists. It assigns three levels of exposure (0, none; 1, low; 2, high) based on the International Standard Classification of

Occupations V.1988 (ISCO-88) and on the probability of exposure to 10 different agents in each job (biological dusts, mineral dusts, gases and fumes, herbicides, insecticides, fungicides, aromatic solvents, chlorinated solvents, other solvents and metals) and two composite categories (VDGF: vapours, dusts, gases and fumes; and “all pesticides”: herbicides, insecticides, fungicides) [23]. The official matching key from the UK Office for National Statistics [21] was used to cross-map SOC2000 and the ISCO-88 before assigning the JEM to each participant.

Cumulative exposure for each occupational exposure agent was calculated using duration of each job and the squared intensity of exposure (0, 1 or 4). This variable was expressed in exposure unit-years (EU-years) and categorised as never exposed, low (<median), moderate (\geq median to <90th percentile) and high (\geq 90th percentile) exposure. This provided a lifetime exposure history for each occupational agent for every participant.

Statistical analysis

We excluded participants with no available spirometry records (n=44 970), those without high-quality spirometry (n=200 898), those who had used an inhaler in the preceding hour (n=2155), those with unknown smoking status (n=1080) and those who did not complete the OSCAR questionnaire on occupation (n=188 166). Baseline questionnaire data, lifetime occupational histories and high-quality spirometry data were available for 65 145 individuals (figure 1).

The association between SAO and lifetime occupational exposures was evaluated using a logistic regression model adjusted for various potential confounders determined *a priori*: age, sex, smoking status (never, ex-smoker or current smoker), smoking pack-years, UK Biobank assessment centre (n=22), Townsend deprivation index (based on small area data) and ethnicity (white *versus* non-white). Results were reported as odds ratios (OR) and 95% confidence intervals (CI). A threshold of significance of 0.05 was considered. A second logistic regression model was run to account for potential co-exposures and minimise collinearity, with adjustments made for significant associations determined in the previous model. Analyses were carried out using RStudio (version 2021.09.0–351) [24] and R (version 4.1.1) [25].

Results

The majority of the 65 145 participants included in this study were female (60.3%), 94.4% were of white ancestry, 61% had never smoked and the median Townsend deprivation index was -2.47 reflecting relative




FIGURE 1 Flow diagram showing selection of final population for analysis. #: criteria for highest quality spirometry: at least two spirograms with no cough, back extrapolated volume <5% FVC (or >5% but <150 mL), reproducible FEV₁ and FVC and a forced expiratory time \geq 6 s on the best curve (curve with highest FEV₁ and FVC). FEV₁: forced expiratory volume in 1 s; FVC: forced vital capacity.

affluence. Women were more likely to have never smoked than men (61% versus 52%). In total, airflow obstruction ($FEV_1/FVC < LLN$) was present in 8%. SAO was present in varying proportions of the population depending on the definition used: 5.6% using $FEF_{25-75} < LLN$ and 21.4% using $FEV_3/FEV_6 < LLN$ (table 1). When the population was restricted to those who had never smoked and who had no history of exposure to the occupational agents of interest, the prevalence estimates of SAO were slightly lower: 4.7% using $FEF_{25-75} < LLN$ and 19.2% using $FEV_3/FEV_6 < LLN$. Half the population had been exposed to at least one occupational agent of interest (48.5%); 16.5% were exposed to a single agent, 21.4% to two agents, 10.0% to three agents and fewer than 1% to four agents (supplementary figure). Exposure to the composite group VDGF was most prevalent (47.7%), followed by all solvents (29.7%), then metals (11.0%) and then all pesticides (3.5%) (figure 2).

Univariable analyses showed significant associations between SAO (using both definitions) and lifetime occupational exposure to: VDGF and specifically to mineral dust, gases and fumes; all pesticides, and insecticides, herbicides and fungicides when considered as separate exposures; and metals. A significant association was observed for biological dust using $FEF_{25-75} < LLN$ and $FEV_3/FEV_6 < LLN$. A significant association was also seen for lifetime exposure to aromatic solvents and $FEV_3/FEV_6 < LLN$ but not for $FEF_{25-75} < LLN$ (supplementary table).

In the multivariable analyses, significant associations remained for both parameters for highest exposures to all pesticides and insecticides and fungicides when considered individually. In most cases, there was an exposure–response observed with increasing cumulative pesticide exposure unit-years. There was also an inverse significant association between $FEV_3/FEV_6 < LLN$ and highest exposure to aromatic solvents and metals, but no exposure–response association observed (table 2).

When accounting for co-exposures, SAO defined as $FEV_3/FEV_6 < LLN$ was significantly associated with the highest cumulative exposure to all pesticides (OR 1.24, 95% CI 1.06–1.44) and negatively associated with the highest cumulative exposure to metals (OR 0.77, 95% CI 0.62–0.94) and the highest cumulative exposure to aromatic solvents (OR 0.85, 95% CI 0.73–0.99) (table 3).

Discussion

In this large UK population-based study, the prevalence of SAO varied from 5.6% to 21.4% depending on the definition used, and SAO was consistently negatively associated with lifetime exposure to pesticides, particularly insecticides and fungicides, in an exposure–response manner.

TABLE 1 Summary of characteristics for the participants with spirometry and occupational data available in the UK Biobank

| Characteristics | Female | Male | Total |
|---------------------------------|-------------------|-------------------|-------------------|
| Participants n | 39 256 | 25 889 | 65 145 |
| Age at recruitment years | 56±8 | 57±8 | 56±8 |
| Ethnicity | | | |
| White | 36 723 (93.5) | 24 450 (94.4) | 61 173 (93.9) |
| Non-white | 2533 (6.5) | 1438 (5.6) | 3971 (6.1) |
| Smoking status | | | |
| Never | 23 980 (61.1) | 13 529 (52.2) | 37 509 (57.6) |
| Ex-smoker | 13 021 (33.2) | 10 280 (39.7) | 23 301 (35.8) |
| Current smoker | 2255 (5.7) | 2080 (8.1) | 4335 (6.6) |
| Pack-years of smoking | 17.1±13.5 | 21.5±17.5 | 19.1±15.6 |
| Townsend deprivation index | −2.5 (−3.8– −0.3) | −2.6 (−3.9– −0.6) | −2.5 (−3.9– −0.4) |
| FEV_1 L | 2.5 (2.2–2.8) | 3.4 (3.0–3.9) | 2.8 (2.4–3.3) |
| FEV_3 L | 3.0 (2.7–3.4) | 4.1 (3.7–4.6) | 3.4 (2.9–4.0) |
| FEV_6 L | 3.2 (2.9–3.6) | 4.4 (4.0–5.0) | 3.6 (3.1–4.3) |
| FVC L | 3.3 (2.9–3.7) | 4.5 (4.0–5.0) | 3.6 (3.1–4.4) |
| FEF_{25-75} L·s ^{−1} | 2.2 (1.7–2.7) | 2.9 (2.2–3.5) | 2.4 (1.9–3.0) |
| $FEV_1/FEV_6 < LLN$ | 5685 (14.5) | 4307 (16.6) | 9992 (15.3) |
| $FEV_3/FEV_6 < LLN$ | 8280 (21.1) | 5662 (21.9) | 13 942 (21.4) |
| $FEF_{25-75} < LLN$ | 2396 (6.1) | 1253 (4.8) | 3649 (5.6) |

Data are presented as mean±SD, median (IQR) and n (%) unless otherwise indicated. FEV_1 : forced expiratory volume in 1 s; FEV_3 : forced expiratory volume in 3 s; FEV_6 : forced expiratory volume in 6 s; FVC: forced vital capacity; FEF_{25-75} : mean forced expiratory flow between 25% and 75% of the forced vital capacity.




FIGURE 2 Participants in the included UK Biobank study population (n=65 145) with cumulative exposure to one or more JEM agents. JEM: Job Exposure Matrix; VGDF: vapour, dust, gases and fumes.

Workers exposed to pesticides commonly report respiratory symptoms, but do not necessarily show abnormal lung function [26, 27]. Previous studies in the UK Biobank Cohort [28] and in other cohort studies [29, 30] have found associations between occupational pesticide exposure and airflow obstruction and COPD. However, a recent systematic review and meta-analysis of respiratory function and exposure to pesticides found only tentative evidence that exposure to cholinesterase-inhibiting pesticides reduced FEV₁/FVC and no evidence that paraquat exposure affected lung function in farmers [31]. One possible mechanism explaining this relationship may involve differential DNA methylation [32]. We adjusted our models for several known and potential confounders. However, it is possible that the observed association between pesticide exposure and SAO is due to unmeasured confounding factors. Many of the workers exposed to pesticides will be farmers and agricultural workers who may also be exposed to agents that are established causes of airways diseases and which can cause SAO on spirometry. For example, crop farmers are likely exposed to grain dust, which is considered a cause of occupational asthma, while animal stock farmers may also be exposed to endotoxins, which has been associated with non-atopic asthma, and *Thermophilic actinomycetes* on mouldy hay, which has been linked to hypersensitivity pneumonitis [33, 34]. Our finding of an inverse relationship between SAO and the highest cumulative exposure to aromatic solvents and to metals was intriguing and is in contrast with other literature reporting both increased fixed airflow obstruction [35] and increased decline in FEV₁ [36] with these exposures. We hypothesise that this is likely due to the healthy worker survivor bias, which may be more pronounced in those with heavy industrial exposures or due to those with heavy exposures being less likely to be included in the UK Biobank population.

The UK Biobank study included just over 120 000 individuals with a lifetime occupational history, but this included those with lower quality spirometry records and because of the intra-individual variability in small airways measurements we limited our analysis to those with high-quality spirometry. We were able to obtain high-quality spirometry from a large number of participants. The ALOHA+ JEM permits a semi-quantitative exposure assessment to be made and allowed stratification of cumulative exposure based on intensity and duration over a lifetime. The UK Biobank is a population cohort and minimises bias due to the healthy worker effect. Small airways measurements (FEF₂₅₋₇₅ and FEV₃) are dependent on performance of high-quality and reproducible spirometry. To reduce the chance of false positive cases of

TABLE 2 Association of small airways obstruction with lifetime occupational exposures in UK Biobank

| ALOHA+ JEM agent | FEF ₂₅₋₇₅ <LLN | | FEV ₃ /FEV ₆ <LLN | |
|-----------------------------|---------------------------|---------|---|---------|
| | OR (95% CI) | p-value | OR (95% CI) | p-value |
| VDGF | | | | |
| Low (<2 EU-years) | 1.02 (0.93–1.11) | 0.7 | 0.99 (0.95–1.05) | 0.8 |
| Moderate (2–17 EU-years) | 1.06 (0.97–1.16) | 0.2 | 0.98 (0.93–1.03) | 0.4 |
| High (≥18 EU-years) | 0.85 (0.71–1.00) | 0.06 | 0.98 (0.89–1.07) | 0.6 |
| Biological dust | | | | |
| Low (<18 EU-years) | 1.09 (0.99–1.19) | 0.08 | 1.00 (0.98–1.03) | 0.8 |
| Moderate (18–44 EU-years) | 1.07 (0.97–1.19) | 0.2 | 1.04 (0.98–1.10) | 0.2 |
| High (≥45 EU-years) | 0.95 (0.77–1.16) | 0.6 | 0.94 (0.84–1.05) | 0.3 |
| Mineral dust | | | | |
| Low (<2 EU-years) | 1.05 (0.93–1.18) | 0.05 | 0.95 (0.89–1.02) | 0.1 |
| Moderate (2–5 EU-years) | 1.04 (0.91–1.19) | 0.5 | 0.96 (0.89–1.03) | 0.3 |
| High (≥6 EU-years) | 0.94 (0.73–1.19) | 0.6 | 0.97 (0.85–1.11) | 0.7 |
| Gases and fumes | | | | |
| Low (<2 EU-years) | 1.00 (0.92–1.10) | 1.0 | 0.98 (0.93–1.03) | 0.5 |
| Moderate (2–16 EU-years) | 0.99 (0.90–1.09) | 0.9 | 0.97 (0.92–1.03) | 0.4 |
| High (≥17 EU-years) | 0.89 (0.74–1.06) | 0.2 | 0.93 (0.84–1.02) | 0.1 |
| All pesticides | | | | |
| Low (≤1 EU-years) | 0.87 (0.66–1.12) | 0.3 | 0.95 (0.82–1.09) | 0.4 |
| Moderate (2–15 EU-years) | 0.99 (0.53–1.70) | 1.0 | 1.08 (0.77–1.49) | 0.7 |
| High (≥16 EU-years) | 1.38 (1.07–1.76) | 0.01 | 1.23 (1.06–1.43) | 0.007 |
| Insecticides | | | | |
| Low (<2 EU-years) | 0.93 (0.70–1.21) | 0.6 | 0.94 (0.80–1.10) | 0.4 |
| Moderate (2–15 EU-years) | 1.07 (0.56–1.88) | 0.8 | 1.25 (0.88–1.74) | 0.2 |
| High (≥16 EU-years) | 1.40 (1.08–1.78) | 0.008 | 1.22 (1.04–1.42) | 0.01 |
| Herbicides | | | | |
| Low (<16 EU-years) | 0.88 (0.34–1.85) | 0.8 | 0.83 (0.52–1.28) | 0.4 |
| Moderate (16–31 EU-years) | 1.60 (1.21–2.06) | 0.001 | 1.32 (1.11–1.57) | 0.001 |
| High (≥32 EU-years) | 0.72 (0.28–1.54) | 0.4 | 1.01 (0.65–1.52) | 1.0 |
| Fungicides | | | | |
| Low (≤1 EU-years) | 0.91 (0.68–1.19) | 0.5 | 0.90 (0.76–1.05) | 0.2 |
| Moderate (2–15 EU-years) | 0.93 (0.41–1.84) | 0.9 | 1.12 (0.73–1.64) | 0.6 |
| High (≥16 EU-years) | 1.47 (1.12–1.88) | 0.003 | 1.26 (1.07–1.47) | 0.006 |
| Chlorinated solvents | | | | |
| Low (≤1 EU-years) | 0.90 (0.78–1.04) | 0.2 | 1.01 (0.94–1.09) | 0.7 |
| Moderate (2–16 EU-years) | 1.03 (0.86–1.22) | 0.7 | 0.99 (0.90–1.09) | 0.9 |
| High (≥17 EU-years) | 0.96 (0.70–1.28) | 0.8 | 0.85 (0.71–1.00) | 0.06 |
| Aromatic solvents | | | | |
| Low (≤1 EU-years) | 0.96 (0.85–1.09) | 0.6 | 1.03 (0.96–1.10) | 0.5 |
| Moderate (2–3 EU-years) | 0.84 (0.67–1.05) | 0.1 | 1.07 (0.95–1.19) | 0.3 |
| High (≥4 EU-years) | 0.92 (0.72–1.15) | 0.5 | 0.85 (0.75–0.97) | 0.02 |
| Other solvents | | | | |
| Low (≤1 EU-years) | 1.00 (0.95–1.05) | 0.6 | 0.97 (0.88–1.07) | 1.0 |
| Moderate (2–3 EU-years) | 1.04 (0.97–1.11) | 0.7 | 1.03 (0.91–1.16) | 0.3 |
| High (≥4 EU-years) | 0.98 (0.90–1.08) | 0.9 | 0.99 (0.83–1.16) | 0.7 |
| Metals | | | | |
| Low (<2 EU-years) | 0.93 (0.79–1.07) | 0.3 | 1.02 (0.94–1.10) | 0.6 |
| Moderate (2–19 EU-years) | 1.00 (0.81–1.22) | 1.0 | 0.97 (0.87–1.08) | 0.6 |
| High (≥20 EU-years) | 0.95 (0.67–1.32) | 0.8 | 0.75 (0.62–0.91) | 0.003 |

Model adjusted for age, sex, smoking status, smoking pack-years, UK Biobank assessment centre, Townsend deprivation index and ethnicity. p-values calculated by Wald test. FEF₂₅₋₇₅: mean forced expiratory flow between 25% and 75% of the forced vital capacity; FEV₃: forced expiratory volume in 3 s; FEV₆: forced expiratory volume in 6 s; EU-years: exposure unit-years; VDGF: vapours, gases, dusts and fumes; LLN: lower limit of normal; JEM: job exposure matrix.

SAO we included only those with highest quality spirometry. Given our concerns about underestimation of FVC we defined SAO using FEF₂₅₋₇₅ and FEV₃/FEV₆ but suggest that overall the best estimate of SAO in this population is FEV₃/FEV₆.

TABLE 3 Association of small airways obstruction, defined as FEV₃/FEV₆ <LLN, with lifetime occupational exposures (multivariable model, adjusted for co-exposures)

| ALOHA+ JEM agent | FEV ₃ /FEV ₆ <LLN | |
|--------------------------|---|---------|
| | OR (95% CI) | p-value |
| All pesticides | | |
| Low (≤1 EU-years) | 0.95 (0.82–1.10) | 0.5 |
| Moderate (2–15 EU-years) | 1.06 (0.76–1.47) | 0.7 |
| High (≥16 EU-years) | 1.24 (1.06–1.44) | 0.008 |
| Aromatic solvents | | |
| Low (≤1 EU-years) | 1.01 (0.93–1.10) | 0.8 |
| Moderate (2–3 EU-years) | 1.03 (0.90–1.18) | 0.7 |
| High (≥4 EU-years) | 0.85 (0.73–0.99) | 0.04 |
| Other solvents | | |
| Low (≤1 EU-years) | 0.99 (0.93–1.06) | 0.8 |
| Moderate (2–3 EU-years) | 1.06 (0.98–1.15) | 0.1 |
| High (≥4 EU-years) | 1.06 (0.95–1.17) | 0.3 |
| Metals | | |
| Low (<2 EU-years) | 1.01 (0.93–1.10) | 0.8 |
| Moderate (2–19 EU-years) | 0.98 (0.87–1.10) | 0.7 |
| High (≥20 EU-years) | 0.77 (0.62–0.94) | 0.01 |

Model adjusted for age, sex, smoking status, smoking pack-years, UK Biobank assessment centre, Townsend deprivation index, ethnicity and the other exposures. p-values calculated by Wald test. FEV₃: forced expiratory volume in 3 s; FEV₆: forced expiratory volume in 6 s; LLN: lower limit of normal; EU-years: exposure unit-years; JEM: job exposure matrix.

Despite these limitations, spirometry-derived parameters remain useful in large population-based studies for assessing SAO where other techniques would not be practical and have not been performed. Studies have shown good associations between these spirometric parameters and alternative methods of assessing SAO. YEE *et al.* [6] showed that FEV₃/FEV₆ <LLN was associated with lower FEV₁, poorer health status, more emphysema and more functional small airways disease on quantitative imaging, and was also associated with development of COPD according to spirometry results (post-bronchodilator FEV₁/FVC <0.7) during study follow-up. In another study by QIN *et al.* [37], individuals with SAO (defined using FEF_{25–75}) in comparison to those with normal spirometry had more emphysema, a smaller airway lumen and larger airways walls in proportion to airway area. In addition, at the 9th generation of airway branching, FEF_{25–75} correlated with computed tomography (CT) scan markers of airways disease [37]. This is important as the 8–9th generation of airway branching is where the largest density of small airways is found. Finally, LU *et al.* [38] compared IOS and spirometry to identify SAO and whilst there was only slight agreement (kappa 0.322, p<0.001), there was no significant difference in CT scan abnormalities between IOS-defined SAO and spirometry-defined SAO suggesting that spirometry is not inferior to other methods as a diagnostic tool.

One limitation of our study is that UK Biobank is not representative of the whole of the UK population on several sociodemographic (*e.g.* ethnicity) and health-related characteristics (*e.g.* smoking), with evidence of a “healthy volunteer” selection bias. Although UK Biobank is not appropriate for estimating population disease prevalence, its large size and array of exposure measures do provide an unparalleled resource for inference of associations between various exposures and diseases [39].

The identification of particular jobs and occupational exposures that increase the risk of SAO offers the opportunity to identify occupations that may contribute to subclinical lung damage during the working life, but which may be the precursor of more serious disease later in older age. Knowing the relationship of such exposures with SAO, and detection of SAO in the context of normal FEV₁ and FVC, allows identification of an “at risk” group. This knowledge can be used to inform targeted preventative policies and monitoring strategies aiming at early intervention to reduce respiratory morbidity and mortality in working populations. Identification of SAO may offer a more effective tool for screening people who have early signs of disease in relation to workplace exposures. Spirometry is already used as part of routine respiratory health surveillance to identify early changes suggestive of asthma and other obstructive lung diseases and is widely available and relatively cheap to perform. Given the lack of consensus between different definitions of SAO [18] further work is required to establish the most clinically relevant spirometric parameter to identify SAO in the general population.

Further longitudinal studies of workers exposed to pesticides are required in order to infer causality and to understand mechanism better. Meanwhile, occupational exposure to pesticides should be kept as low as is practicable through substitution, engineering controls and use of personal protective equipment. We also propose that measurement of small airways could form part of the screening process in health surveillance.

Conclusions

Occupational pesticide exposure is associated with SAO in the UK Biobank population cohort, highlighting the need for intervention strategies for primary prevention and to reduce progression to more severe lung disease.

Provenance: Submitted article, peer reviewed.

Support statement: This study was supported by Colt Foundation grant CF/01/21. Funding information for this article has been deposited with the Crossref Funder Registry.

Conflict of interest: None declared.

References

- 1 Blanc PD, Annesi-Maesano I, Balmes JR, *et al.* The occupational burden of nonmalignant respiratory diseases. An official American Thoracic Society and European Respiratory Society statement. *Am J Respir Crit Care Med* 2019; 199: 1312–1334.
- 2 van den Berge M, Ten Hacken NHT, Cohen J, *et al.* Small airway disease in asthma and COPD: clinical implications. *Chest* 2011; 139: 412–423.
- 3 Güder G, Brenner S, Störk S, *et al.* Diagnostic and prognostic utility of mid-expiratory flow rate in older community-dwelling persons with respiratory symptoms, but without chronic obstructive pulmonary disease. *BMC Pulm Med* 2015; 15: 83.
- 4 Kwon DS, Choi YJ, Kim TH, *et al.* FEF(25–75%) values in patients with normal lung function can predict the development of chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis* 2020; 15: 2913–2921.
- 5 Hegab S YL, DiGiovine B, Morris ZQ. Prognostic significance of a reduced FEV3/FVC ratio (Meeting abstract A6418). *Am J Respir Crit Care Med* 2015: 191.
- 6 Yee N, Markovic D, Buhr RG, *et al.* Significance of FEV(3)/FEV(6) in recognition of early airway disease in smokers at risk of development of COPD: analysis of the SPIROMICS cohort. *Chest* 2022; 161: 949–959.
- 7 Stockley JA, Ismail AM, Hughes SM, *et al.* Maximal mid-expiratory flow detects early lung disease in α (1)-antitrypsin deficiency. *Eur Respir J* 2017; 49: 1602055.
- 8 Skylogianni E, Triga M, Douros K, *et al.* Small-airway dysfunction precedes the development of asthma in children with allergic rhinitis. *Allergol Immunopathol (Madr)* 2018; 46: 313–321.
- 9 McDonough JE, Yuan R, Suzuki M, *et al.* Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. *N Engl J Med* 2011; 365: 1567–1575.
- 10 Xiao D, Chen Z, Wu S, *et al.* Prevalence and risk factors of small airway dysfunction, and association with smoking, in China: findings from a national cross-sectional study. *Lancet Respir Med* 2020; 8: 1081–1093.
- 11 Quanjer PH, Weiner DJ, Pretto JJ, *et al.* Measurement of FEF25–75% and FEF75% does not contribute to clinical decision making. *Eur Respir J* 2014; 43: 1051–1058.
- 12 Dilektasli AG, Porszasz J, Casaburi R, *et al.* A novel spirometric measure identifies mild COPD unidentified by standard criteria. *Chest* 2016; 150: 1080–1090.
- 13 Gulati M TA. Small airways disease related to occupational exposures. *Clin Pulm Med* 2015; 22: 133–140.
- 14 de Jong K, Boezen HM, Kromhout H, *et al.* Occupational exposure to vapors, gases, dusts, and fumes is associated with small airways obstruction. *Am J Respir Crit Care Med* 2014; 189: 487–490.
- 15 Sunyer J, Kogevinas M, Kromhout H, *et al.* Pulmonary ventilatory defects and occupational exposures in a population-based study in Spain. Spanish Group of the European Community Respiratory Health Survey. *Am J Respir Crit Care Med* 1998; 157: 512–517.
- 16 Sudlow C, Gallacher J, Allen N, *et al.* UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med* 2015; 12: e1001779.
- 17 Amaral AFS, Strachan DP, Burney PGJ, *et al.* Female smokers are at greater risk of airflow obstruction than male smokers. UK Biobank. *Am J Respir Crit Care Med* 2017; 195: 1226–1235.
- 18 Knox-Brown B, Mulhern O, Feary J, *et al.* Spirometry parameters used to define small airways obstruction in population-based studies: systematic review. *Respir Res* 2022; 23: 67.
- 19 Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. *Am J Respir Crit Care Med* 1999; 159: 179–187.
- 20 Hansen JE, Porszasz J, Casaburi R, *et al.* Re-defining lower limit of normal for FEV(1)/FEV(6), FEV(1)/FVC, FEV(3)/FEV(6) and FEV(3)/FVC to improve detection of airway obstruction. *Chronic Obstr Pulm Dis* 2015; 2: 94–102.

- 21 Office for National Statistics. Standard Occupational Classification 2000. www.ons.gov.uk/methodology/classificationsandstandards/standardoccupationalclassification/socarchive Date last accessed: 20 April 2023.
- 22 De Matteis S, Jarvis D, Young H, *et al.* Occupational self-coding and automatic recording (OSCAR): a novel web-based tool to collect and code lifetime job histories in large population-based studies. *Scand J Work Environ Health* 2017; 43: 181–186.
- 23 de Jong K, Boezen HM, Kromhout H, *et al.* Association of occupational pesticide exposure with accelerated longitudinal decline in lung function. *Am J Epidemiol* 2014; 179: 1323–1330.
- 24 RStudio Team (2020). RStudio: Integrated Development for R. RStudio, PBC, Boston, MA. www.rstudio.com/ Date last accessed: 11 November 2022.
- 25 R Core Team (2021). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. www.R-project.org/ Date last accessed: 11 November 2022.
- 26 Negatu B, Kromhout H, Mekonnen Y, *et al.* Occupational pesticide exposure and respiratory health: a large-scale cross-sectional study in three commercial farming systems in Ethiopia. *Thorax* 2017; 72: 498–499.
- 27 Zuskin E, Mustajbegovic J, Schachter EN, *et al.* Respiratory function in pesticide workers. *J Occup Environ Med* 2008; 50: 1299–1305.
- 28 Sadhra SS, Mohammed N, Kurmi OP, *et al.* Occupational exposure to inhaled pollutants and risk of airflow obstruction: a large UK population-based UK Biobank cohort. *Thorax* 2020; 75: 468–475.
- 29 Alif SM, Dharmage SC, Benke G, *et al.* Occupational exposure to pesticides are associated with fixed airflow obstruction in middle-age. *Thorax* 2017; 72: 990–997.
- 30 Lytras T, Kogevinas M, Kromhout H, *et al.* Occupational exposures and 20-year incidence of COPD: the European Community Respiratory Health Survey. *Thorax* 2018; 73: 1008–1015.
- 31 Ratanachina J, De Matteis S, Cullinan P, *et al.* Pesticide exposure and lung function: a systematic review and meta-analysis. *Occup Med (Lond)* 2020; 70: 14–23.
- 32 van der Plaats DA, de Jong K, de Vries M, *et al.* Occupational exposure to pesticides is associated with differential DNA methylation. *Occup Environ Med* 2018; 75: 427–435.
- 33 Kirkhorn SR, Garry VF. Agricultural lung diseases. *Environ Health Perspect* 2000; 108: Suppl. 4, 705–712.
- 34 Eduard W, Douwes J, Omenaas E, *et al.* Do farming exposures cause or prevent asthma? Results from a study of adult Norwegian farmers. *Thorax* 2004; 59: 381–386.
- 35 Alif SM, Dharmage SC, Benke G, *et al.* Occupational exposures to solvents and metals are associated with fixed airflow obstruction. *Scand J Work Environ Health* 2017; 43: 595–603.
- 36 Alif SM, Dharmage S, Benke G, *et al.* Occupational exposure to solvents and lung function decline: a population based study. *Thorax* 2019; 74: 650–658.
- 37 Qin S, Yu X, Ma Q, *et al.* Quantitative CT analysis of small airway remodeling in patients with chronic obstructive pulmonary disease by a new image post-processing system. *Int J Chron Obstruct Pulmon Dis* 2021; 16: 535–544.
- 38 Lu L, Peng J, Zhao N, *et al.* Discordant spirometry and impulse oscillometry assessments in the diagnosis of small airway dysfunction. *Front Physiol* 2022; 13: 892448.
- 39 Fry A, Littlejohns TJ, Sudlow C, *et al.* Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. *Am J Epidemiol* 2017; 186: 1026–1034.